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Natural Regulatory T cells (Treg) are defined by stable expression of the cell surface proteins 
CD4 and CD25, low surface expression of CD127 and expression of the transcription factor 
FOXP3. The contribution of Treg to the prevention of autoimmunity and the maintenance of 
immune homeostasis is the subject of ongoing interest, as alterations in Treg numbers and 
function are implicated in a wide range of diseases. The in vitro benchmark for determining 
Treg function is suppression of proliferation of unmatched effector T cells in a mixed 
leukocyte reaction (MLR) over a 3-6 day time period. As an alternative to this assay we show 
that a 7 hr CD154 expression assay is rapid, simple, and provides a reliable readout of 
suppressor function. Using multiple Treg-like cell types including nTreg,  iTreg and Treg cell 
lines we show that suppression of CD154 expression is a surrogate for suppression of 
proliferation. We propose this as a suitable alternative to the MLR assay, as it is rapid and 
may be more amenable to high throughput screening, analysing large cohorts of clinical 
samples, or assaying transiently suppressive populations.  
  
Introduction 
A healthy immune system depends on highly reactive cells that are able to distinguish foreign 




tolerance in the periphery is an active process 
mediated by cells collectively described as having regulatory function. FOXP3
 
expressing T 
regulatory cells (Tregs) are critical mediators of dominant self-
 
tolerance. The essential role 
for these cells in preventing autoimmunity and maintaining immune homeostasis is 
demonstrated by loss of Treg cells as a result of FOXP3 mutation, which is lethal in both 
humans and mice 
5
. Breakdown of the balance of reactivity and self tolerance in the immune 
system is believed to lead to a wide variety of autoimmune diseases, including type 1 
diabetes, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, many of 





Tregs are phenotypically defined by their expression of cell surface markers CD4 and CD25, 
low expression of the IL-
 
7 receptor (CD127) 
10
, and expression of the transcription factor 
FOXP3 
11
. At least two different FOXP3-expressing Treg populations exist in the periphery, 
and these develop from different sources. Natural Tregs (nTreg) develop in the thymus and 
are considered a separate CD4 lineage. Inducible Treg (iTreg) are formed from naive CD4 




- ) 12-14. Although FOXP3 is crucial for the development and 
function of both mouse and human Tregs 
15-23
, FOXP3 can also be expressed transiently by 
activated human CD4 T cells without conferring suppressive function 
24-25
, complicating the 
use of FOXP3 as a conclusive marker for regulatory function in human cells. Irrespective of 
the origin of Tregs, measurement of reduced effector cell proliferation in vitro is accepted as 
conclusive functional evidence of a T regulatory cell phenotype. Cell proliferation and Treg 
function in vitro is conventionally measured either through the incorporation of [
3
H]-
thymidine during DNA synthesis or the reduction of 5,6-carboxyfluorescein diacetate 
  
succunimidyl ester (CFSE) label with cell division in a mixed lymphocyte reaction (MLR). 
Both [
3
H]-thymidine and CFSE MLRs demonstrate Treg suppression by enumerating a 
reduction in effector cell proliferation in the presence of Tregs 
26
.  
Although currently the benchmark for assay of in vitro suppressor function, the MLR has 
some drawbacks. Three cell populations are required for the MLR assay: effector cells, 
irradiated ‘feeder’ cells, and T regulatory cells.  This introduces assay variability due to donor 
specific differences in effector cell proliferation and response to stimulation, as well as 
variation in feeder cell function post-
 
irradiation. These factors make MLR assays difficult to 
standardise, which is necessary for investigating Treg function in clinical settings. 
Additionally, small variations in assay parameters can be amplified by the 3-6 day culture 
period.  
In order to improve the robustness and application of suppressor assays we have investigated 
the use of CD154 as a reporter of suppressor function. CD154 (CD40L) is a member of the 
tumour necrosis factor family 
27
. This transmembrane protein is one of the first surface 
proteins up-regulated on T cells in response to stimulus 
28-30
, providing co-stimulatory 
signalling to B cells and antigen presenting cells through CD40 
31
. Importantly, CD154 is not 
expressed by resting T cells 
28
, and is only expressed transiently following activation, with 
expression peaking 6-8 hours after stimulation. Unlike the CFSE and [
3
H]-thymidine assays, 
which measure proliferation, the CD154 functional assay measures an early signal preceding 
proliferation because CD154 is a marker of activation. This has been used to measure T cell 
activation 
28
 and recently by Ruitenberg 
32
 to measure Treg activity. 





 effector cells 7 hours after activation. We demonstrate here that 
suppression of CD154 expression measures comparable suppressor function of freshly 
isolated and expanded Tregs purified from cord and peripheral blood to that seen when 
  
proliferation is used as a readout of suppression, either by thymidine incorporation or CFSE 
dilution. Given the growing interest in transient Treg populations such as iTreg and Tr1, 










with membrane dyes such as DIOC18(3) prior to input into the assay. We report strong 
suppressive function by in vitro generated iTreg with DIOC18(3) stained Teffector cells. We 
also report suppression in the CD154 assay by Treg-like cell line Karpas-299.  The CD154 
assay provides a simple and easily standardised method for analysing the functional potential 
of freshly isolated or ex vivo expanded Treg cells. The rapid nature of the assay and its 
response to many cells with Treg like characteristics suggest its potential utility for high 
throughput screens for agents to modulate Treg function and rapid screening of ex vivo 




Isolation of Teffector cells from adult blood buffy coat 
Buffy Coats from young male donors were collected (Australian Red Cross and Women's and 
Children's Hospital (WCH) human ethics approved) and processed within 24 hours of 
collection. CD4
+ 
T cells were enriched using the RosetteSep CD4
+ 
T cell enrichment kit 





Teffector cells, enriched CD4
+ 
T cell populations were depleted of 
CD25
+ 
cells by labelling with anti-CD25 microbeads and separation on an Automacs Pro 
Separator (Miltenyi Biotech, Bergisch Gladbach, Germany). When required, cells were 
cryopreseved  by resuspension in 90% FCS 10% DMSO followed by rate freezing in 
  
isopropanol (Nalgene, Rochester, NY) for 4 hours at -
 
80C, then transferred to liquid 
nitrogen for long term storage.  
 
Isolation of adult peripheral blood Treg cells 
Adult peripheral blood CD4
+ 
T cells were enriched using the RosetteSep CD4
+ 
T cell 
enrichment kit (Stem Cell Technologies, Vancouver, Canada) and ficoll density gradient 
centrifugation as above. Adult peripheral blood Treg cells were then isolated from the 
enriched CD4
+ 





cells using a FACS Aria II cell sorter (BD). Tregs were cultured at 
1x10
6
/mL in RPMI supplemented with 10% foetal bovine serum and 100 U/mL human 
recombinant IL-2 (eBioscience, San Diego, CA) for 48 hours. Prior to use in suppression 
assays, Tregs were washed twice in 50mL complete RPMI to remove IL-2, and viable cells 
were determined by trypan blue counting.  
 
Isolation and expansion of Tregs from cord blood. 
Umbilical cord blood samples were collected from the Adelaide Women’s and Children’s 
Hospital (WCH) Birthing Suite with approved ethics from the Women’s and Children’s 
Health Network Human Subjects Committee. Regulatory T cells were purified from the 
mononuclear cell fraction (CBMCs) isolated from fresh cord blood by ficoll density gradients 
as described previously 
26




) were purified using the 
Invitrogen Dynal Bead Regulatory T cell isolation kit (Invitrogen, Carlsbad, CA, USA). 
Isolated regulatory T cells were expanded for 7 days with Dynal Bead Human T Expander 
CD3/CD28 beads at a 3:1 bead:cell ratio (Invitrogen) and 500U/mL IL-
 
2 (eBioscience) in X-
 
VIVO 15 (Lonza, Basel, Switzerland) supplemented with 5% human serum, 2mM L-
glutamine and 20mM Hepes (complete X-
 
VIVO 15). At day 7 of expansion, CD3/CD28 
  
beads were removed and cells were allowed to rest for a further 7 days in complete X-
 
VIVO 




Flow cytometry of expanded nTregs and iTregs 
Before use in suppressor assays the phenotype of expanded Treg cells was confirmed by flow 
cytometry. Expression of CD4 (CD4-APC-
 
H7, BD Biosciences clone SK3) and CD25 
(CD25-PECy7, BD Biosciences clone M-
 
A251) were determined by staining cells for 
30mins on ice, followed by 2 washes in PBS/BSA. Intracellular FOXP3 staining was 
subsequently performed using the FOXP3 fix/perm kit and FOXP3-Alexa Fluor 488 and 647 
antibodies (BD Biosciences clone 259D/C7). Cells were analysed on a FACSAriaII flow 
cytometer (BD Biosciences). 
 
CD154 suppression assay  









 effector cells were 




 effector cells were rested for 12-20 hours 
at 37
o
C in complete RPMI after thawing. The CD154 assay was carried out in 96 well 
CellStar U-bottomed plates containing a constant number of effector cells (5x10
4
/well) and 
serial dilutions of Tregs, giving rise to Teffector:Treg ratios of 1:1, 2:1, 4:1, 8:1, 16:1. To 
induce CD154 expression stimulated wells received anti-CD3/CD28 T cell expander beads 
(Invitrogen) at a 0.25:1 bead:cell ratio, and anti-CD154-APC (BD; clone 89-76). Effector 
cells stimulated in the absence of Tregs and unstimulated effector cells from wells which 
received anti-CD154-APC alone were used as positive and negative controls respectively, 
and set up in triplicate. The cultures were incubated at 37
o
C/CO2 in the dark for 7-8 hours. 
Following the incubation period, cells were stored at 4
o
C for a maximum of 15 hours prior to 
  
staining and analysis on a BD FACSAriaII flow cytometer. Cells were stained for surface 
expression of CD4 and CD25 prior to FACS analysis by three-colour flow cytometry on a 




) cells were 




 cells. Unstimulated, stained effector cells were used 
to set the gate for analysis of CD154 expression. Suppression of T cell activation was 




 effectors alone with 




 effectors co-cultured with Tregs. 
 





 effector cells (2x10
4 
per well), were cultured in U-bottom 96 well plates in the 
presence of 1x10
5
 irradiated (30 Gy) unmatched PBMCs. Treg cells were washed twice in 
RPMI media to remove IL-2 before addition to the assays. Treg test cells were added to 
achieve Teffector:Treg ratios of 1:1, 2:1, 4:1, 8:1, 16:1. Cells were stimulated with 100ng/mL 
soluble anti-CD3 (OKT3) monoclonal antibody (eBioscience). On day 4 [
3
H]-thymidine was 
added to the wells for the last 16 hours of culture. All Teffector:Treg ratios were performed 
in triplicate and measured using a Microbeta beta counter (Perkin Elmer). Results were 
expressed in scintillation counts per minute.  
 
Mixed lymphocyte assay: 5,6-carboxy fluorescein diacetate succinimidyl ester (CFSE)  







 cells were isolated as described above, and labelled with 
1M CFSE (Invitrogen, Carlsbad, CA) in PBS for 10 minutes at 37C. The reaction was 
quenched by addition of an equal volume of heat inactivated FBS. CFSE labelled effector 
cells (2x10
4
 per well) were incubated with 1x10
5
 irradiated (30 Gy) unmatched PBMCs. Treg 
cells were added at Teffector:Treg ratios of 1:1, 2:1, 4:1, 8:1, 16:1, in the presence of 
  
100ng/mL anti-CD3 (OKT3) monoclonal antibody (eBioscience) in a final volume of 200μl 
RPMI per well in a 96-well U-bottom plate. Co-cultures were harvested after 5 days of 
incubation and the proliferation of the effector population was visualised by the dilution of 
CFSE fluorescence with cell division on a BD FACSAriaII flow cytometer.   
 
Karpas-299 cell line  
The Karpas-299 cell line, an anaplastic large T cell lymphoma cell line with regulatory T 
cell- like properties 
34
 was used as a substitute regulatory T cell in suppressor assays. This 
cell line was purchased from HPA Culture collections (Porton Down, UK) and cultured in 
RPMI supplemented with 2mM Glutamine and 10% FCS. When used in suppressor assays, 
Teffector:Karpas-299 dilutions from 1:1 to 16:1 were tested. 
 




T effector cells  




 T cells were isolated from cord blood CBMCs using 
the Invitrogen Dynal Bead Regulatory T cell isolation kit (Invitrogen) and cultured for 7 days 
in complete X-VIVO 15 supplemented with CD3/CD28 beads (3:1 bead to cell ratio), 
500U/mL IL-2, 5ng/mL TGF-β and 10nM all-trans-retinoic acid (ATRA) (Sigma). At day 7, 
CD3/CD28 beads were removed and cells were allowed to rest for a further 7 days in 
complete X-VIVO 15 media with 100U/mL IL-2, followed by cryopreservation. Phenotyping 
of iTregs showed robust expression of FOXP3 and heterogeneous CD25 expression. Induced 
Treg populations were thawed and rested overnight in complete RPMI before use in assays. 
 
DIOC18(3) labelling of effector cell populations 
3,3’- dioctadecyloxacarbocyanine perchlorate (DIOC18(3)) labelling was performed when 
resolution of Treg and Teffector populations could not be achieved with CD25 gating (e.g. 
  




Teffector cells, isolated by MACS as described above, were 
labelled with 2µg/mL DIOC18(3) (Molecular Probes) in PBS containing 3% FBS for 45 min 
at 37°C in a 5% CO2 incubator. Cells were washed 3 times in PBS supplemented with 3% 
FCS prior to use in the assay. The DIOC18(3) stained effectors were set up as per standard 
CD154 suppression assay, however no surface CD4 and CD25 staining was performed prior 
to FACS analysis.  
 
 
Calculation of % Suppression: 





treg/cpm stimulation effectors 



















Ex vivo CB Tregs express CD25 and FOXP3 following expansion.  
Cord blood Tregs expanded for 7 days with CD3/CD28 beads, followed by a further 7 day 
rest period in the absence of expansion beads, expressed high levels of CD25 and FOXP3 
(figure 1a,b)(n=8). The addition of a 7 day ‘rest’ period post-expansion resulted in a 
reduction in Treg proliferation, rendering these cells suitable to be included in thymidine 
incorporation assays (figure 1c). 
 





We first demonstrated that cell surface staining with CD4 and CD25 antibodies allowed for 
resolution of effector cells from Treg cells in co-culture on the basis of CD25 expression. 
  
CD4+CD25- effector cells were analysed alone in the presence and absence of stimulation 
(fig 2a).  A gating strategy that was tightly confined to the CD25- region was selected, as 
although the mean fluorescence intensity on Treg is a log brighter than CD25- cells (see 
fig1), we wished to minimise the unintentional inclusion of CD25+ cells in the CD154 
analysis to maximise assay signal to noise. Over the seven hour stimulation there was no up-
regulation of CD25 on effector cells (figure 2a lower panel ii). This confirmed that the CD25- 
gating strategy restricted visualisation of CD154 suppression events to the effector cells. 
When CD25- effector cells alone were assayed in the absence of stimulation, no detectable 




cells, confirming minimal 
background signal (figure 2a upper panel iii), and confirming that the induction of CD154 
was stimulation-dependant (figure 2a lower panel iii). The level of CD154 expression seen 









cells do not require bystander cells for optimal CD154 induction 
by CD3/CD28 beads. When expanded CB Tregs were titrated into this culture, they 




effectors in a titratable manner (figure 
2b). At maximal suppression (Tregs to effector cell ratio 1:1) CD154 expression ranged from 
5 to 26% with a median of 11.4%. The mean fluorescence intensity (MFI) of CD154 
expression also decreased upon addition of Treg cells, with a 2 to 3 fold reduction in MFI 
observed. By serially diluting Tregs to give a range of Teffectors:Tregs ratios from 1:1 to 





cells we observed some donor variability in stimulation-induced CD154 
expression, and expression of CD154 in the presence of 1:1 Tregs ranged from 5 to 26.2%, 
with a median of 11.2% (figure 2d). However the percentage suppression was more 
consistent, ranging from 49 to 78%, with a median of 61% for different donors at maximal 
Treg suppressor function. 
  
 
Comparing CD154 assay measurement of suppressive function with benchmark MLR assays 
The ability of the CD154 assay to detect Treg suppressive function was then confirmed by 




thymidine assays, two assays routinely used to measure 
Treg suppressive function in vitro. Representative assay readouts for CFSE and H
3
-thymidine 
assays are shown in Supplementary figures 1 and 2 respectively. In order to make an accurate 
comparison between suppressor assay readouts, paired donor matched assays were 
performed. Measuring the maximal response to stimulation and suppression in Treg co-
cultures and expressing each as percentage suppression, allowed direct comparison of the 
three assays (figure 3). Equivalent suppressive function was observed in the CD154 and 





incorporation assays than both CD154 and CFSE assays. CFSE assays were prepared with the 




thymidine assay, with the exception of CFSE staining of the effector 




thymidine assays may reflect the 
short window where DNA synthesis is measured, rather than increased sensitivity of the 
assay readout. These data indicate that the CD154 assay is a suitable surrogate assay to the 
traditional MLR assay. 
 
The CD154 assay can be used to detect suppressor function in adult blood Treg populations  
We next determined if the CD154 assay could be used to detect suppression by Tregs isolated 




cells) were isolated from 
peripheral blood PBMCs by FACS. Sorted Tregs were rested in 100U/mL IL-2 for 48hours 
post sorting prior to use in the CD154 assay. This approach has been used to improve 
viability and suppressive function in sorted Treg populations 
35
. A short incubation in IL-
 
2 is 
sufficient to promote suppressive function in adult Treg cells without need for stimulation or 
  
expansion. Pre-incubation with IL-2 was required for suppressor function in CD154 assays 
and increased suppressive function in CFSE assays (data not shown)..  Using isolated PB 





CD154 induction at various Teffector:Treg ratios using just 5x10
4
 effector cells/well (figure 
4). These data suggests that the CD154 assay is sufficiently sensitive to be used with rare 
Treg populations from peripheral blood, enabling its application to clinical cohort studies.  
 
CD154 assay enables measurement of suppressive function in T cell lines 
Large numbers of Treg cells are required to enable high-throughput screens of compounds or 
genes which modulate Treg function. The use of immortalised cell lines and a cheap and 
efficient suppression assay would greatly facilitate this. The Karpas-299 cell line has been 
reported to display Treg characteristics, including expression of Treg-associated genes, 
production of anti-inflammatory cytokines and suppressive function in classical MLR assays 
34
. Karpas-299 cells express high levels of CD4 and CD25, and expression of FOXP3 was 
confirmed by intracellular flow cytometry (figure 5a,b). The addition of Karpas-299 cells at 
various Teffector:Karpas-299 cell ratios in the CD154 assay, resulted in suppression of 




 effector cell (figure 5c), with an average of 45% 
suppression of CD154 expression observed at a 1:1 ratio (figure 5d).  
 




Teffector cells enables analysis of suppressive potential 
of induced Treg populations  
High expression of CD25 in Treg populations is necessary to allow for their resolution from 
the CD25
-
 effector cell population. However, some suppressor cell populations can have low 
to intermediate expression of CD25, such as CD25
-
 Tr1 cells or in vitro generated induced 
Tregs (iTregs), hence an alternative to CD25 based gating is required. We therefore 
  
investigated whether non-antibody based labelling of effector cells could be used. To test 




 cord blood cells in the presence of IL-2, TGF- 




 cells under these conditions 




Thymidine assays (figure 6d). However, as the levels of CD25 expression on iTregs are 
highly heterogeneous, iTreg cells cannot be easily distinguished from CD25
- 
Teffector cells 
in the CD154 assay. We initially labelled the CD25
-
 cells with CFSE, however, CFSE 
labelling has been reported to decrease the viability of labelled cells and modulate the 
expression of activation molecules 
36
. We observed that CFSE staining abolished induction of 
CD154 in response to stimulation (data not shown). An alternative cell labelling dye, 
DIOC18(3) has been shown to stably integrate into the cell membrane where it remains 
integrated for up to 48 hours 
37
. DIOC18(3) staining has been reported to have little effect on 




effector cell populations 
without affecting CD154 expression following stimulation (figure 6b). Using DIOC18(3) 
labelled effector cells, and assaying CD154 expression in the DIOC18(3)- positive gate, we 
show that iTregs are able to suppress CD154 expression levels in Teffector cells. Two 
representative assays are shown in fig 6c, and a comparison of iTreg in all three functional 
assays is shown in fig 6d. Therefore, DIOC18(3) labelling appears to be an effective approach 
to resolve effector and suppressor populations in the CD154 assay. Using DIOC18(3) stained 
Teffectors has the added advantage of removing the need for antibody staining with CD4 and 
CD25 at the end of the assay, simplifying the assay set up and substantially decreasing the 





Although widely accepted as the benchmark for human Treg function, the 5 day MLR 
suppressor assay is relatively complex and is sensitive to the degree of alloreactivity between 
donors. Generation of high quality and statistically robust data requires multiple assays to 
minimise the effects of donor to donor variation in both Treg and effector cell function. The 
cell labelling techniques required for each of these assays introduces additional variability, as 
wide differences in intensity and distribution of CFSE staining or thymidine scintillation 
counts are regularly observed between experiments. This creates additional difficulties for 




H]-thymidine incorporation method, DNA synthesis is measured in the last 16 
hours of culture and function is therefore not measured across the whole 3-6 day co-culture. 
This means that any cells that have been suppressed or have died prior to the [
3
H]-thymidine 
pulse will not be assayed. Additionally, the MLR using [
3
H]-thymidine measures total cell 
proliferation in a mixed population of cells, which may not restrict the readout to the 
enumeration of division of the effector population in question, and iTreg, Treg like cell lines 
or Tr1 cells may not be as anergic as nTregs. Although regulatory T cells are generally 
anergic in vitro 
38
, Tregs will proliferate upon TCR stimulation in the presence of IL2, for 
example when cultured under expansion conditions or in the MLR itself 
39
. CFSE pre 
labeling of effector cells in a mixed lymphocyte reaction is able to circumvent some of these 
issues, as it specifically tracks the proliferation of only the effector cell population in co-
culture. However, staining procedures can be difficult to control, producing variation in cell 
viability, uniformity of labeling and mean fluorescence intensity, all of which are critical 
elements to enumerating proliferation. A further confounder for both MLR assays is in any 
long co-culture assay, stimulated effector cells may die from activation induced cell death or 
  
IL-2 depletion. This can contribute to assay background, or cause cells which have not 
responded to stimulation to appear to be suppressed.  
This suggests the need for a surrogate for these assays that is simple, rapid, scalable and can 
be read out on a flow cytometer. The observation that activated CD4
+
 cells transiently up 
regulate CD154 on the cell surface following stimulation, with surface expression rapidly lost 
by internalisation provides such an assay readout. This phenomenon occurs within 4-8hr of 
stimulation well before activation-induced up regulation of CD25 on the cell surface. 
Although Tregs can influence proliferation of activated non-CD25
-
 T cells in some immune 
settings, measuring suppression of proliferation in vitro with a short assay window is not 
possible. However, observing suppression of early activation marker expression in recently 
activated naive CD25- effector cells enables rapid identification of suppressive function. The 
assay utilises the addition of a fluorochrome-conjugated anti-CD154 antibody to the culture 
media, and although the CD154-antibody complex may be internalised upon surface protein 
turnover, by keeping the assay window short (7-8 hours), there is little or no degradation of 
the internalised antibody and hence no need to use agents such as monensin to block 
intracellular protein degradation machinery 
32
.  
We have confirmed that Treg mediated suppression of CD154 expression correlates with 
suppression of proliferative activity by comparing the assay against CFSE and thymidine 
based MLR assays using donor matched CB Tregs. In this comparison, the suppressive 
functional readout by CD154 assay was equivalent to the degree of suppression observed 
with the MLR assays, indicating that the short assay correlates with the longer term 
proliferation results.  
 Many different markers have been used to sub divide Treg populations, including CD127, 
CD45RA and ICOS 
35, 40-41
, however these approaches have so far failed to capture all 
FOXP3
+






has long been utilised to identify a population of Treg cells with strong FOXP3 expression, 
TSDR demethylation and suppressive function 
41-45
. Utilising this strategy may yield a 
heterogenous population of Tregs with a spectrum of Ag experiences and phenotypes. We 
observed that the CD154 assay can measure the suppressive potency of Tregs isolated from 




gating strategy and this did not require the 5 day 
expansion prior to co-culture reported by Ruitenberg. A short incubation in IL-2 has been 
utilised to rest Treg cells post sorting 
35
, and when using this treatment we observed increased 
suppressive function and cell viability in the CD154 assay. We also investigated whether the 
CD154 assay could be utilised to test a cell line with reported suppressive function, Karpas-
299. Although it is not yet clear whether Karpas-299 can be a useful surrogate for primary 
Tregs, the CD154 assay is able to report suppressive function by this cell line.  
Lastly, we show that a simple non-toxic Teffector cell membrane labelling step with long-
chain dialkylcarbocyanines such as DIOC18(3) allows for the easy resolution of Teffector 
cells in the assay co culture. This extends the application of this assay to include populations 
of Tregs with diverse CD25 expression, such as in vitro generated iTreg cells.  Furthermore, 
labelling Teffector cells in this manner eliminates the need for surface staining for CD4 and 
CD25, further simplifying assay set up and analysis, rendering the assay more time and cost 
effective. Hence the CD154 assay is amenable to use with multiple Treg sub-populations. 
Unlike other MLR suppression assays, only two cell populations are required in the CD154 
assay, significantly reducing complexity of set up and reducing assay variability. This assay 
was initially developed using total PBMC as the effector cell pool 
32
, however we have now 




 cells as the effector population. Both PBMC and 
CD25
-
 effector cell populations give sensitive responses to stimulation and can report 
induction of CD154 and its repression by Treg cells. A disadvantage of utilising PBMC is 
that not all of the cells are CD4+CD25- effector cells. This will introduce inaccuracies in 
  
Teffector:Treg ratios and a high degree of donor variability. Purifying the effector cells 
allows for more accurate calculation of Teffector to Treg ratios enabling clearer visualisation 





cells enables a 10-fold reduction in effector cells required and allows for banking of a 
homogeneous effector cell population. As donor variation in response to stimulation is 
commonly observed with primary human samples, using banked purified effector cells allows 
for storage from the same donor for multiple assays, which minimises this donor variable. 
Using purified effector cells also enables measurement of suppressive effects on the effector 
cell population directly and excludes any influence of the non-
 
T cell compartments of 
peripheral blood.  
Using the CD154 assay protocol with CD25- effector cells, 5-
 
fold fewer Tregs are required 
than where PBMCs were used as the effector population 
32
. As Tregs are often the limiting 
cell population for functional studies, lowering the number of cells required increases the 
possible applications of this assay, including the characterisation of different Treg 
subpopulations. In addition, a combined reduction of input cell numbers results in a 
significant reduction in the amount of antibody required, which would provide a major cost 
advantage when assaying large cohorts of samples.  
A rapid and simple assay of suppressor function would be invaluable for applications such as 
high content screening for new drugs or antibodies to inhibit Treg function.  In addition, an 
assay of acquisition or ablation of Treg function is essential for establishing importance of 
genes involved in regulating suppressive function. However, the existing 5 day MLR assays 
are not suitable for transfected populations, as expression of the gene of interest is often lost 
well before the assay endpoint is reached. The rapid activation readout, sensitivity to Treg 
suppression and robust staining with anti-CD154 antibody results in an assay amenable to 
  
using transiently transfected cells. The ability to use a Treg cell line in the assay further 
increases its utility.  
In summary, we find that the CD154 assay is a suitable alternative assay of in vitro Treg 
function, can report suppression by many Treg and Treg-like cells, and is fast, robust and 
reproducible. The CD154 assay could allow for direct high throughput screening of 
modulators of function in Treg cells for developing new therapeutics to either reduce Treg 
function (for infectious diseases or cancer therapy), to enhance Treg function (for organ 
transplantation and autoimmune disease therapy), or direct clinical applications, such as 
diagnostic screening or post-therapy monitoring of Treg cell function.  
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Figure 1: Expanded cord blood Tregs maintain Treg phenotypes. (A) After the 14 day culture 
period, CB Tregs express CD4 and CD25. (B) These cells robustly express FOXP3. (C) 
These cells are anergic by [
3
H]-thymidine assay in the presence of irradiated PBMCs and 





Figure 2: Expanded cord blood Tregs suppress Teffector cell CD154 expression. (A) Gating 




cells in the absence of CD25+Treg. 
CD4
+ 
cells are isolated (i), gated for low CD25 expression (ii) and then analysed for CD154 
expression (iii). The CD154 positive gate is set using the unstimulated control. (B) 




by CB Tregs. Co-
 
culture at various ratios 
of Teffector:Treg, one representative experiment (n=8). (C) Percent suppression of CD154 
expression by CB Tregs, one representative experiment (n=8). (D) The range of CD154 
induction by stimulation with anti-
 
CD3/CD28 beads (maximal activation), and in the 
presence of Tregs at 1:1 ratio (maximal suppression). Average of 8 experiments with SEM. 






Figure 3. CD154 assay measures comparable suppressive function to CFSE and Thymidine 
Assays. Identical CB Treg samples were utilised, n=6, and percentage suppression was 





Figure 4. Adult PB Tregs suppress CD154 expression in Teffector cells. Adult Tregs were 




cells.  (A) Teffector cells 
upregulate CD154 in response to stimulation with anti-CD3 and anti-CD28 beads. (B) 






Figure 5: CD154 assay can measure suppressive function ‘Treg- like’ cell line KARPAS-299 
cell line. (A) KARPAS-299 cells express CD4 and CD25, and (B) express FOXP3. (C) 
KARPAS-299 cells suppress CD154 expression in Teffector cells at various 
Teffector:Karpas-299 ratios, one representative experiment shown. (D) Percentage 
Suppression by KARPAS-299 cells measured by CD154 assay, average of three experiments 




Figure 6: Membrane labelling of Teffector cells enables measurement of suppressive 
function by induced Tregs (iTreg). (A) CB induced Treg cultures show a range of CD25 




Teffector cells with 
DIOC18(3) dye does not alter CD154 induction in response to antiCD3/CD28 beads.  Using 
DIOC18(3) labelled Teffectors allows for resolution of Teffector cells from iTregs. (C) The 
addition of iTregs caused suppression of CD154 expression at various Teffector:Treg ratios 
in the DIOC18(3)
+ 
fraction; two representative experiments, (n=4).  
  
References: 
1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained 
by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single 
mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155(3): 
1151-64. 
 
2. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in 
immunological tolerance to self and non-self. Nat Immunol 2005; 6(4): 345-52. 
 
3. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity 
throughout the lifespan of mice. Nat Immunol 2007; 8(2): 191-7. 
 
4. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning 
lymphocytes off. Science 1998; 280(5361): 243-8. 
 
5. Powrie F, Read S, Mottet C, Uhlig H, Maloy K. Control of immune pathology by regulatory T 
cells. Novartis Found Symp 2003; 252: 92-8; discussion 98-105, 106-14. 
 
6. Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past 
challenges, future prospects. J Clin Immunol 2008; 28(6): 677-84. 
 
7. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, 
Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 
2010; 30(1): 80-9. 
 
8. Sarkar S, Fox DA. Regulatory T cells in rheumatoid arthritis. Curr Rheumatol Rep 2008; 10(5): 
405-12. 
 
9. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by 
CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199(7): 
971-9. 
 
10. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely 
correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 
203(7): 1701-11. 
 
11. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, 
specification, subphenotypes. Nat Immunol 2009; 10(7): 689-95. 
 
12. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD4+CD25- 
naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. J Exp Med 2003; 198(12): 1875-86. 
 
13. Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM. IL-2 controls the stability of Foxp3 
expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol 2011; 186(11): 6329-37. 
 
14. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P et al. Retinoic acid enhances Foxp3 




15. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD et al. Foxp3 
occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 
445(7130): 931-5. 
 
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription 
factor Foxp3. Science 2003; 299(5609): 1057-61. 
 
17. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al. Disruption of a 
new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder 
of the scurfy mouse. Nat Genet 2001; 27(1): 68-73. 
 
18. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al. The immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by 
mutations of FOXP3. Nat Genet 2001; 27(1): 20-1. 
 
19. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N et al. X-linked neonatal 
diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of 
mouse scurfy. Nat Genet 2001; 27(1): 18-20. 
 
20. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in 
mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8(3): 
277-84. 
 
21. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A et al. Functional delineation and 
differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. 
Immunity 2009; 30(6): 899-911. 
 
22. Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T et al. Genome-Wide 
Identification of Human FOXP3 Target Genes in Natural Regulatory T Cells. J Immunol 2010. 
 
23. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of 
Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445(7130): 
936-40. 
 
24. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by 
all activated human T-cells. Clin Immunol 2007; 123(1): 18-29. 
 
25. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of 
FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37(1): 129-38. 
 
26. Bresatz S, Sadlon T, Millard D, Zola H, Barry SC. Isolation, propagation and characterization 
of cord blood derived CD4+ CD25+ regulatory T cells. J Immunol Methods 2007; 327(1-2): 53-
62. 
 
27. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C et al. The CD40 antigen 
and its ligand. Annu Rev Immunol 1994; 12: 881-922. 
 
28. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells 
with diverse cytokine profiles. Nat Med 2005; 11(10): 1113-7. 
 
  
29. Chattopadhyay PK, Yu J, Roederer M. Live-cell assay to detect antigen-specific CD4+ T-cell 
responses by CD154 expression. Nat Protoc 2006; 1(1): 1-6. 
 
30. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is 
elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler 
Thromb Vasc Biol 2006; 26(7): 1626-31. 
 
31. Foy TM, Page DM, Waldschmidt TJ, Schoneveld A, Laman JD, Masters SR et al. An essential 
role for gp39, the ligand for CD40, in thymic selection. J Exp Med 1995; 182(5): 1377-88. 
 
32. Ruitenberg JJ, Boyce C, Hingorani R, Putnam A, Ghanekar SA. Rapid assessment of in vitro 
expanded human regulatory T cell function. Journal of Immunological Methods 2011: 1-12. 
 
33. Venken K, Thewissen M, Hellings N, Somers V, Hensen K, Rummens JL et al. A CFSE based 
assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen 
specific and polyclonal T cell responses. J Immunol Methods 2007; 322(1-2): 1-11. 
 
34. Wolke C, Tadje J, Bukowska A, Tager M, Bank U, Ittenson A et al. Assigning the phenotype of 
a natural regulatory T-cell to the human T-cell line, KARPAS-299. Int J Mol Med 2006; 17(2): 
275-8. 
 
35. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R et al. Only the CD45RA+ 
subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines 
upon in vitro expansion. Blood 2006; 108(13): 4260-7. 
 
36. Last'ovicka J, Budinsky V, Spisek R, Bartunkova J. Assessment of lymphocyte proliferation: 
CFSE kills dividing cells and modulates expression of activation markers. Cell Immunol 2009; 
256(1-2): 79-85. 
 
37. Ozdemir O. Evaluation of human mast cell-mediated cytotoxicity by DIOC18 target cell 
labeling in flow cytometry. J Immunol Methods 2007; 319(1-2): 98-103. 
 
38. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F et al. Thymus and 
autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key 
function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162(9): 
5317-26. 
 
39. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro 
expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004; 104(3): 895-
903. 
 
40. Ukena SN, Hopting M, Velaga S, Ivanyi P, Grosse J, Baron U et al. Isolation strategies of 
regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. 
Exp Hematol 2011; 39(12): 1152-60. 
 
41. d'Hennezel E, Yurchenko E, Sgouroudis E, Hay V, Piccirillo CA. Single-cell analysis of the 
human T regulatory population uncovers functional heterogeneity and instability within 
FOXP3+ cells. J Immunol 2011; 186(12): 6788-97. 
 
  
42. Jana S, Campbell H, Woodliff J, Waukau J, Jailwala P, Ghorai J et al. The type of responder T-
cell has a significant impact in a human in vitro suppression assay. PLoS One 2010; 5(12): 
e15154. 
 
43. Baecher-Allan CM, Hafler DA. Functional analysis of highly defined, FACS-isolated 
populations of human regulatory CD4+CD25+ T cells. Clin Immunol 2005; 117(2): 192; 
discussion 193. 
 
44. Hoffmann HJ, Malling TM, Topcu A, Ryder LP, Nielsen KR, Varming K et al. 
CD4dimCD25bright Treg cell frequencies above a standardized gating threshold are similar in 
asthmatics and controls. Cytometry A 2007; 71(6): 371-8. 
 
45. Ukena SN, Velaga S, Geffers R, Grosse J, Baron U, Buchholz S et al. Human regulatory T cells 
in allogeneic stem cell transplantation. Blood 2011; 118(13): e82-92. 
 
 
 
